BRIEF-Takeda Pharmaceutical Co: Recorded 402.5 Billion Yen Additional Provision For Legal Proceedings After U.S. Jury Verdict In Antitrust Litigation

June 5 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:

  • TAKEDA PHARMACEUTICAL CO LTD - ADDITIONAL PROVISION FOR LEGAL PROCEEDINGS AND REVISION OF EARNINGS REPORT (KESSAN TANSHIN) FOR FISCAL YEAR ENDED MARCH 31, 2026 (IFRS,CONSOL)

  • TAKEDA PHARMACEUTICAL CO - RECORDED AN ADDITIONAL PROVISION FOR LEGAL PROCEEDINGS OF JPY 402.5 BILLION AND RECOGNIZED RELATED TAX BENEFITS OF JPY 58.4 BILLION IN THE CONSOLIDATED FINANCIAL STATEMENTS FOR FY2025

  • TAKEDA PHARMACEUTICAL CO - THIS REVISION HAS NO IMPACT ON TAKEDA’S CORE FINANCIAL RESULTS FOR FY2025, NO CHANGES TO THE FY2026 FINANCIAL FORECAST OR MANAGEMENT GUIDANCE, INCLUDING THE FORECAST FOR ADJUSTED FREE CASH FLOW

Source text: ID:nTSre89a71

Further company coverage: 4502.T


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.